Immunocore Limited announced the appointment of Professor Sir John Bell, the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research, to its Board of Directors with immediate effect. Professor Bell, distinguished scientists in the fields of genomic and genetic research and immunology, also brings significant experience in healthcare business, having been a founding director at three biotechnology companies; Avidex Limited, Oxagen Limited and PowderJect Pharmaceuticals plc. He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
47.98 USD | -4.94% | -11.56% | -29.77% |
13/05 | Mizuho Cuts Price Target on Immunocore to $88 From $90, Keeps Buy Rating | MT |
08/05 | Immunocore Holdings' Shares Fall After Q1 Net Loss Widens | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.77% | 252.41Cr | |
+38.34% | 72TCr | |
+34.28% | 59TCr | |
-4.49% | 37TCr | |
+20.11% | 33TCr | |
+2.21% | 28TCr | |
+17.02% | 24TCr | |
+9.31% | 21TCr | |
-5.07% | 21TCr | |
+0.03% | 17TCr |
- Stock Market
- Equities
- IMCR Stock
- News Immunocore Holdings plc
- Immunocore Limited Appoints Sir John Bell to its Board of Directors